Confo Therapeutics Entered into a Global License Agreement with Eli Lilly for CFTX-1554
- Confo will receive $40M up front & is also eligible to receive ~$590M in milestones per program along with royalties
- After a clinical proof-of-concept, Confo has the option to co-invest in the funding of development programs in exchange for additional royalties while Lilly will be responsible to continue the clinical development program beyond P-I
- The agreement also helps to advance Confo's current therapeutic antibody candidates that target the same receptor. CFTX-1554 is a novel inhibitor of the angiotensin II type 2 receptor & is currently being studied in the P-I clinical development for the treatment of neuropathic pain
Ref: Businesswire | Image: Eli Lilly
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.